Organon & Co. (NYSE:OGN) Shares Bought by New York Life Investment Management LLC

New York Life Investment Management LLC increased its stake in Organon & Co. (NYSE:OGNFree Report) by 37.4% during the 3rd quarter, Holdings Channel reports. The fund owned 68,292 shares of the company’s stock after purchasing an additional 18,590 shares during the quarter. New York Life Investment Management LLC’s holdings in Organon & Co. were worth $1,186,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Kahn Brothers Group Inc. grew its stake in Organon & Co. by 0.6% during the 4th quarter. Kahn Brothers Group Inc. now owns 62,634 shares of the company’s stock worth $1,749,000 after buying an additional 366 shares during the last quarter. Glassman Wealth Services grew its position in Organon & Co. by 36.8% during the second quarter. Glassman Wealth Services now owns 1,665 shares of the company’s stock worth $35,000 after buying an additional 448 shares during the period. Kentucky Retirement Systems Insurance Trust Fund grew its holdings in shares of Organon & Co. by 5.2% in the 3rd quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 9,114 shares of the company’s stock worth $213,000 after acquiring an additional 449 shares during the period. Fairfield Bush & CO. increased its position in shares of Organon & Co. by 3.0% in the first quarter. Fairfield Bush & CO. now owns 16,302 shares of the company’s stock valued at $569,000 after buying an additional 481 shares in the last quarter. Finally, Cresset Asset Management LLC raised its position in Organon & Co. by 3.7% during the first quarter. Cresset Asset Management LLC now owns 13,969 shares of the company’s stock worth $488,000 after acquiring an additional 493 shares during the last quarter. Institutional investors and hedge funds own 77.08% of the company’s stock.

Organon & Co. Price Performance

OGN opened at $16.95 on Wednesday. The stock has a market capitalization of $4.33 billion, a PE ratio of 7.40, a P/E/G ratio of 0.47 and a beta of 0.79. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $29.88. The firm’s fifty day moving average price is $14.51 and its 200 day moving average price is $16.66.

Analysts Set New Price Targets

Several brokerages have recently issued reports on OGN. Bank of America reduced their price objective on Organon & Co. from $23.00 to $19.00 in a research report on Thursday, October 12th. Morgan Stanley reduced their target price on Organon & Co. from $27.00 to $22.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 11th. The Goldman Sachs Group lowered shares of Organon & Co. from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $33.00 to $16.00 in a research report on Friday, November 3rd. Finally, Piper Sandler dropped their target price on Organon & Co. from $32.00 to $22.00 and set an “overweight” rating on the stock in a report on Wednesday, November 22nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Organon & Co. has an average rating of “Moderate Buy” and an average target price of $23.33.

Read Our Latest Stock Report on Organon & Co.

Organon & Co. Company Profile

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Further Reading

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNFree Report).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.